NBP 615
Alternative Names: NBP-615; SK-NBP615Latest Information Update: 23 Feb 2022
At a glance
- Originator SK Chemicals
- Developer SK Bioscience
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer
Most Recent Events
- 23 Feb 2022 No development reported - Phase-I/II for Cervical cancer (In adolescents, In children, Prevention, In adults) in South Korea (IM) (NCT04453241)
- 07 Jul 2020 NBP 615 is still in phase I/II trials for Cervical cancer (Prevention, In adolescents, In adults, In children) in South Korea (IM) (NCT04453241)